All In Biotech

Drug Trial Radar · NCT04830124

Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6

A Phase 2, Open-Label, Multicenter, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma - ARTISTRY-6

Last checked: Nov 19, 2026Latest source record: Jun 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

173

Actual

Start

Sep 27, 2021

Primary completion

May 8, 2025

Study completion May 8, 2025

Sponsor

Lead sponsor
Mural Oncology, IncIndustry
Sponsor type
Industry
First posted
Apr 2, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study observes the antitumor activity, safety, tolerability, PK, and pharmacodynamics in patients with inoperable and/or metastatic melanoma

Conditions

  • Cutaneous Melanoma
  • Mucosal Melanoma

Interventions

  • Nemvaleukin Alfa SubcutaneousDrug

    Subcutaneous injection of nemvaleukin every 7 days

  • Nemvaleukin Alfa IntravenousDrug

    Intravenous (IV) infusion over 30 minutes given daily for 5 consecutive days

  • Nemvaleukin Alfa Intravenous Less Frequent DosingDrug

    Intravenous (IV) infusion over 30 minutes twice every 21 days (Day 1 and Day 8 dosing of a 21 day cycle)

  • PembrolizumabDrug

    Cohort 4 only: 200mg IV pembrolizumab on Day 1 of a 21-day cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Centrally-assessed overall response rate (ORR) (Cohort 1 and 2)Time frame: Assessed up to 2 years from the first dose
  2. Investigator-assessed overall response rate (ORR) (Cohort 3 and 4)Time frame: Assessed up to 2 years from the first dose

Locations

41 sites in 8 countries. Site status is shown where the registry gives one.

  • UC San Diego Moores Cancer Center

    La Jolla, California

  • The Angeles Clinic and Research Institute

    Los Angeles, California

  • Mayo Clinic

    Jacksonville, Florida

  • Orlando Health, Inc

    Orlando, Florida

  • Norton Cancer Center

    Louisville, Kentucky

  • Massachusetts General Hospital

    Boston, Massachusetts

  • NYU Laura and Isaac Perimutter Cancer Center

    New York, New York

  • Columbia University Medical Center

    New York, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • UT Southwestern Medical Center of Dallas

    Dallas, Texas

  • The Queen Elizabeth Hospital

    Woodville, Australia

  • Calvary Mater Newcastle

    Waratah, New South Wales, Australia

  • John Flynn Private Hospital

    Tugun, Queensland, Australia

  • Princess Margaret Cancer Centre

    Toronto, Ontario, Canada

  • Centre Hospitalier de l'Universite de Montreal (CHUM)

    Montreal, Quebec, Canada

  • McGill University Health Center (MUHC)

    Montreal, Quebec, Canada

  • Istituto Tumori Giovanni Paolo II IRCCS Ospedale Oncologico Bari

    Bari, Italy

  • Fondazione IRCC Istituto Nazionale dei Tumori

    Milan, Italy

  • Veneto Oncology Institute

    Padova, Italy

  • Ospedale S. Maria della Misericordia

    Perugia, Italy

  • IRCCS Istituti Fisioterapici Ospitalieri

    Roma, Italy

  • Azienda Ospedaliera Universitaria Senese Policlinico Le Scotte

    Siena, Italy

  • Chungnam National University Hospital

    Daejeon, South Korea

  • Kyungpook National University Chilgok Hospital

    Daegu, Daegu, South Korea

  • The Catholic Univ. of Korea, Seoul St. Marys Hospital

    Seoul, Seocho-gu, South Korea

  • Severance Hospital Yonsei University Health System

    Seoul, Seodaemun-Gu, South Korea

  • Samsung Medical Center

    Gangam-gu, Seoul, South Korea

  • Seoul National University Hospital

    Jongno-gu, Seoul, South Korea

  • Asan Medical Center

    Songpa-Gu, Seoul, South Korea

  • Hospital Clinic Barcelona

    Barcelona, Spain

  • Hospital Universitario Vall d'Hebron

    Barcelona, Spain

  • Hospital General Universitario

    Madrid, Spain

  • Hospital Regional de Málaga

    Málaga, Spain

  • Hospital Universitario Miguel Servet

    Zaragoza, Spain

  • Hospital Universitario Quiron Pozuelo

    Madrid, Madrid, Spain

  • Kaohsiung Chang Gung Memorial Hospital

    Kaohsiung City, Taiwan

  • Chang Gung Memorial Hospital LinKou

    Taoyuan, Taiwan

  • Taipei Veterans General Hospital, VGHTPE

    Taipei, Taipei, Taiwan

  • Royal Marsden Hospital

    London, United Kingdom

  • The Christie Hospital

    Manchester, United Kingdom

Showing 40 of 41 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.